Pipeline In A Product
Three FcRn inhibitors are on the market and more are in development, with long-term commercial growth expected to come through indication expansion. Now the question is will they deliver on their pipeline-in-a-product promise?
The company is studying two FcRn inhibitors in early clinical development and spoke to Scrip about the competitive market.
As the Belgian firm's blockbuster beats AbbVie's Skyrizi in a head-to-head psoriatic arthritis study.
The Swiss major's immunology chief Angelika Jahreis tells Scrip of her high hopes for the potential pipeline-in-a-product.
Positive Phase III data for Rhapsido in chronic inducible urticaria adds regulatory momentum to what Novartis describes as a key growth driver within its immunology portfolio.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
The US FDA approved Uplizna (inebilizumab) for generalized myasthenia gravis, an increasingly crowded market. Amgen believes it can compete due to the CD19-targeting antibody’s durable efficacy with twice-yearly dosing.
The company said it moved the TL1A inhibitor into three Phase IIb trials in immune-mediated diseases on top of the Phase III trials ongoing in IBD.
The Swiss major's oral BTK inhibitor gets the green light in the US for chronic spontaneous urticaria.
Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.
Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.
CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.